Novartis to buy US-listed Avidity Biosciences for $12 bln
PositiveFinancial Markets

Novartis has announced its acquisition of Avidity Biosciences for $12 billion, marking a significant move in the biotechnology sector. This deal is expected to enhance Novartis's portfolio and strengthen its position in the pharmaceutical market, particularly in innovative therapies. The acquisition highlights the growing trend of large pharmaceutical companies investing in biotech firms to access cutting-edge technologies and treatments, which could lead to improved patient outcomes.
— Curated by the World Pulse Now AI Editorial System











